Carolyn M. Tyler, Charles A. Wuertzer, William J. Bowers and Howard J. Federoff Pages 337 - 350 ( 14 )
Strategies that employ HSV amplicon vectors in the prevention and/or amelioration of pathogenic states afflicting the central nervous system (CNS) have been extensively documented in preclinical disease models. The versatility of the HSV amplicon platform allows for the implementation of therapeutic approaches that require expression of genes exhibiting neuroprotective or neuroplastic activities, or even applications that necessitate the elaboration of antigenspecific immune responses to pathogenic proteins/structures harbored within the CNS. This discourse highlights the successes and challenges encountered using HSV amplicon vectors as tools for the dissection of neural network function and as therapeutics directed against a variety of neurologic disorders.
Neuroprotection, Ischemic Injuries, Creutzfeld-Jacob disease (CJD), Prion Vaccination, Alzheimer, ’, s Disease, CNS inflammation
Departments of Neurology,Microbiology and Immunology, Center for Aging and Developmental Biology;Box 645, University of Rochester School of Medicine and Dentistry,601 Elmwood Ave., Rochester, NY 14642, USA.